Dose ratio between morphine and methadone in patients with cancer pain: A retrospective study

Cancer

Volumn 82, Issue 6, 1998, Pages 1167-1173

  Lawlor, Peter G ^a   Turner, Ken S ^a   Hanson, John ^b   Bruera, Eduardo D ^a  

^a GREY NUNS COMMUNITY HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cancer pain; Dose ratio; Equianalgesic tables; Methadone; Morphine; Opioid rotation

Indexed keywords

METHADONE; MORPHINE;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; DRUG POTENCY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN; RETROSPECTIVE STUDIES;

EID: 0032521273     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3     Document Type: Article

References (33)

1. Foley K. The treatment of cancer pain. N Engl J Med 1985;313:84-95.
2. World Health Organization Expert Committee report. Cancer pain relief and palliative care. Technical series 804. Geneva, Switzerland: World Health Organization, 1990.
3. Cherny NI, Foley KM. Non-opioid and opioid analgesic pharmacotherapy of cancer pain. Hematol Oncol Clin North Am 1996;10:79-101.
4. MacDonald N, Der L, Allan S, Champion P. Opioid hyperexcitability: the application of alternate opioid therapy. Pain 1993;54:353-5.
5. Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration and opiate rotation. J Pain Symptom Manage 1995;10:287-91.
6. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation (OR) for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-84.
7. Morley J, Miles JB, Wells JC, Bowsher D. Paradoxical pain. Lancet 1992;340:1045.
8. Portenoy RK, Foley KM, Stulman J, Khan E, Adelhardt J, Layman M, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations, and the consequences of renal failure. Pain 1991;47:13-9.
9. Glare PA, Walsh TD, Pippenger CE. Normorphine, a neurotoxic metabolite? [letter]. Lancet 1990;335:725-6.
10. Sjogren P, Jensen N-H, Jensen TS. Disappearance of morphine induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994;59:313-6.
11. De Conno F, Groff L, Brunelli C, Zecca E, Ventifridda V, Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996;14:2836-42.
12. Bruera E, Watanabe S, Fainsinger R, Spachynski K, Suarez-Almazor M, Inturrisi C. Custom-made capsules and suppositories of methadone for patients on high dose opioids for cancer pain. Pain 1995;62:141-6.
13. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993;52:137-47.
14. Bruera E, Schoeller T, Fainsinger RL, et al. Palliative care rounds: custom-made suppositories of methadone for severe cancer pain. J Pain Symptom Manage 1992;7:372-4.
15. Sawe J. High dose, morphine and methadone in cancer patients. Clinical pharmacokinetic consideration of oral treatment. Clin Pharmacol Ther 1986;11:87-106.
16. Inturrisi CE, Hanks G. Opioid analgesic therapy. In: Doyle D, Hanks GWC, MacDonald N, editors. Oxford textbook of palliative medicine. Volume 4. Oxford: Oxford University Press, 1993:166-81.
17. Management of Cancer Pain. Clinical practice guidelines (Rockville, MD): U.S. Department of Health & Human Services; 1994 AHCPR Pub No. 94-0592.
18. Cancer pain: a monograph on the management of cancer pain. Health & Welfare Canada: Minister of Supply and Services Canada, Ottawa H42-2/5 (1984).
19. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer 1996;78:852-7.
20. Twycross R, Lack S. Pain relief. In: Twycross R, Lack S, Eds. Therapeutics in terminal cancer, 2nd edition. Edinburgh: Churchill Livingston 1990:2:11-39.
21. Levy M. Pain management in advanced cancer. Semin Oncol 1985;12:394-410.
22. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990;43:273-86.
23. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996;335:1124-32.
24. Bruera E, Macmillan K, Hanson J, MacDonald RN. The Edmonton staging system for cancer pain: preliminary report. Pain 1989;37:203-9.
25. Folstein MF, Folstein S, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
26. Statistical package for the social sciences. Chicago: McGraw-Hill, 1986.
27. Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain. 1997;72:79-85.
28. Ebert B, Anderson S, Kroesgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-d-asparate (NMDA) antagonists in the rat cortex and spinal cord. Neuroscience Lett 1995;187:165-8.
29. Elliot K, Kest B, Man A, et al. N-methyl-d-asparate (NMDA) receptors, mu and Kappa opioid tolerance and perspectives on new analgesic drug development. Neuropsychopharmacology 1995;13:347-56.
30. Trujillo K. Effects of non competitive n-methyl-d-asparate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology 1995;13:301-7.
31. Clark JL, Kalen GE. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J Pain Symptom Manage 1995;10:310-4.
32. Lawlor P, Walker P, Bruera E, et al. Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage. 1997;13:356-61.
33. Smith MJ, Watt JA, Cramond T. Morphine-3-glucuronide -a potent antagonist of morphine analgesia. Life Sci 1990;47:579-85.